TY - JOUR AU - Tullman, M. J. PY - 2013 DA - 2013// TI - Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis JO - Am J Manag Care VL - 19 ID - Tullman2013 ER - TY - JOUR AU - Pasquier, R. A. AU - Pinschewer, D. D. AU - Merkler, D. PY - 2014 DA - 2014// TI - Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis JO - CNS Drugs VL - 28 UR - https://doi.org/10.1007/s40263-014-0160-8 DO - 10.1007/s40263-014-0160-8 ID - Pasquier2014 ER - TY - JOUR AU - Rae-Grant, A. AU - Day, G. S. AU - Marrie, R. A. AU - Rabinstein, A. AU - Cree, B. A. C. AU - Gronseth, G. S. PY - 2018 DA - 2018// TI - Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology JO - Neurology VL - 90 UR - https://doi.org/10.1212/WNL.0000000000005347 DO - 10.1212/WNL.0000000000005347 ID - Rae-Grant2018 ER - TY - JOUR AU - Rommer, P. S. AU - Zettl, U. K. PY - 2018 DA - 2018// TI - Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients JO - Expert Opin Pharmacother VL - 19 UR - https://doi.org/10.1080/14656566.2018.1446944 DO - 10.1080/14656566.2018.1446944 ID - Rommer2018 ER - TY - JOUR AU - Klein, C. AU - Lammens, A. AU - Schäfer, W. AU - Georges, G. AU - Schwaiger, M. AU - Mössner, E. PY - 2013 DA - 2013// TI - Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties JO - mAbs VL - 5 UR - https://doi.org/10.4161/mabs.22771 DO - 10.4161/mabs.22771 ID - Klein2013 ER - TY - JOUR AU - Hauser, S. L. AU - Bar-Or, A. AU - Comi, G. AU - Giovannoni, G. AU - Hartung, H. P. AU - Hemmer, B. PY - 2017 DA - 2017// TI - Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis JO - N Engl J Med VL - 376 UR - https://doi.org/10.1056/NEJMoa1601277 DO - 10.1056/NEJMoa1601277 ID - Hauser2017 ER - TY - JOUR AU - Montalban, X. AU - Hauser, S. L. AU - Kappos, L. AU - Arnold, D. L. AU - Bar-Or, A. AU - Comi, G. PY - 2017 DA - 2017// TI - Ocrelizumab versus placebo in primary progressive multiple sclerosis JO - N Engl J Med VL - 376 UR - https://doi.org/10.1056/NEJMoa1606468 DO - 10.1056/NEJMoa1606468 ID - Montalban2017 ER - TY - JOUR AU - Kappos, L. AU - Li, D. AU - Calabresi, P. A. AU - O’Connor, P. AU - Bar-Or, A. AU - Barkhof, F. PY - 2011 DA - 2011// TI - Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial JO - Lancet VL - 378 UR - https://doi.org/10.1016/S0140-6736(11)61649-8 DO - 10.1016/S0140-6736(11)61649-8 ID - Kappos2011 ER - TY - STD TI - Hauser L, Kappos L, Montalban X, Hughes R, Koendgen H, McNamara J, et al. Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. ECTREMIS Online Library 2018, 229069. https://onlinelibrary.ectrims-congress.eu/ectrims/2018/ectrims-2018/229069/stephen.l.hauser.safety.of.ocrelizumab.in.multiple.sclerosis.updated.analysis.html. Accessed 15 Apr 2019. UR - https://onlinelibrary.ectrims-congress.eu/ectrims/2018/ectrims-2018/229069/stephen.l.hauser.safety.of.ocrelizumab.in.multiple.sclerosis.updated.analysis.html ID - ref9 ER - TY - STD TI - DGN Leitlinie zur Diagnose und Therapie der MS (Guidelines for MS diagnosis and treatment by the German Society of Neurology). https://www.dgn.org/leitlinien/2333-ll-31-2012-diagnose-und-therapie-der-multiplen-sklerose. 21.08.2015. Accessed 08 Feb 2019. UR - https://www.dgn.org/leitlinien/2333-ll-31-2012-diagnose-und-therapie-der-multiplen-sklerose ID - ref10 ER - TY - STD TI - Guidelines for Good Pharmacoepidemiology Practices (GPP), 2015. https://www.pharmacoepi.org/resources/policies/guidelines-08027/. Accessed 08 Feb 2019. UR - https://www.pharmacoepi.org/resources/policies/guidelines-08027/ ID - ref11 ER - TY - JOUR AU - Haase, R. AU - Wunderlich, M. AU - Dillenseger, A. AU - Kern, R. AU - Akgün, K. AU - Ziemssen, T. PY - 2018 DA - 2018// TI - Improving multiple sclerosis management and collecting safety information in the real world: the MSDS3D software approach JO - Expert Opin on Drug Saf VL - 17 UR - https://doi.org/10.1080/14740338.2018 DO - 10.1080/14740338.2018 ID - Haase2018 ER - TY - JOUR AU - Kern, R. AU - Haase, R. AU - Eisele, J. C. AU - Thomas, K. AU - Ziemssen, T. PY - 2016 DA - 2016// TI - Designing an electronic patient management system for multiple sclerosis: building a next generation multiple sclerosis documentation system JO - Interact J Med Res VL - 5 UR - https://doi.org/10.2196/ijmr.4549 DO - 10.2196/ijmr.4549 ID - Kern2016 ER - TY - JOUR AU - Ziemssen, T. AU - Kempcke, R. AU - Eulitz, M. AU - Großmann, L. AU - Suhrbier, A. AU - Thomas, K. PY - 2013 DA - 2013// TI - Multiple sclerosis documentation system (MSDS): moving from documentation to management of MS patients JO - J Neural Transm VL - 120 UR - https://doi.org/10.1007/s00702-013-1041-x DO - 10.1007/s00702-013-1041-x ID - Ziemssen2013 ER - TY - JOUR AU - Ziemssen, T. AU - Kern, R. AU - Cornelissen, C. PY - 2015 DA - 2015// TI - The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice JO - BMC Neurol VL - 15 UR - https://doi.org/10.1186/s12883-015-0342-0 DO - 10.1186/s12883-015-0342-0 ID - Ziemssen2015 ER - TY - JOUR AU - Ziemssen, T. AU - Engelmann, U. AU - Jahn, S. AU - Leptich, A. AU - Kern, R. AU - Hassoun, L. PY - 2016 DA - 2016// TI - Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS) JO - BMC Neurol VL - 16 UR - https://doi.org/10.1186/s12883-016-0629-9 DO - 10.1186/s12883-016-0629-9 ID - Ziemssen2016 ER - TY - JOUR AU - Ziemssen, T. AU - Gass, A. AU - Wuerfel, J. AU - Bayas, A. AU - Tackenberg, B. AU - Limmroth, V. PY - 2016 DA - 2016// TI - Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab JO - BMC Neurol VL - 16 UR - https://doi.org/10.1186/s12883-016-0625-0 DO - 10.1186/s12883-016-0625-0 ID - Ziemssen2016 ER - TY - JOUR AU - Ziemssen, T. AU - Kern, R. AU - Cornelissen, C. PY - 2016 DA - 2016// TI - Study design of PANGAEA 2.0, a non- interventional study on RRMS patients to be switched to fingolimod JO - BMC Neurol VL - 16 UR - https://doi.org/10.1186/s12883-016-0648-6 DO - 10.1186/s12883-016-0648-6 ID - Ziemssen2016 ER - TY - STD TI - BfArM and PEI. Empfehlungen des Bundesinstituts für Arzneimittel und Medizinprodukte und des Paul-Ehrlich-Instituts zur Planung, Durchführung und Auswertung von Anwendungsbeobachtungen (AWB) vom 7. Juli 2010. https://www.pei.de/SharedDocs/Downloads/pu/klinische-pruefung/100707-awb-kommentierung-fachkreise.pdf?__blob=publicationFile&v=1. German. Accessed 13 Mar 2019. UR - https://www.pei.de/SharedDocs/Downloads/pu/klinische-pruefung/100707-awb-kommentierung-fachkreise.pdf?__blob=publicationFile&v=1 ID - ref19 ER - TY - JOUR AU - Atkinson, M. J. AU - Sinha, A. AU - Hass, S. L. AU - Colman, S. S. AU - Kumar, R. N. AU - Brod, M. PY - 2004 DA - 2004// TI - Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease JO - Health Qual Life Outcomes VL - 2 UR - https://doi.org/10.1186/1477-7525-2-12 DO - 10.1186/1477-7525-2-12 ID - Atkinson2004 ER - TY - JOUR AU - Hobart, J. AU - Lamping, D. AU - Fitzpatrick, R. AU - Riazi, A. AU - Thompson, A. PY - 2001 DA - 2001// TI - The multiple sclerosis impact scale (MSIS-29). A new patient-based outcome measure JO - Brain VL - 124 UR - https://doi.org/10.1093/brain/124.5.962 DO - 10.1093/brain/124.5.962 ID - Hobart2001 ER - TY - BOOK AU - Guy, W. PY - 1976 DA - 1976// TI - Editor. ECDEU assessment manual for psychopharmacology PB - US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration CY - Rockville ID - Guy1976 ER - TY - JOUR AU - Benedict, R. H. B. AU - DeLuca, J. AU - Phillips, G. AU - LaRocca, N. AU - Hudson, L. D. AU - Rudick, R. PY - 2017 DA - 2017// TI - Validity of the symbol digit modalities test as a cognition performance outcome measure for multiple sclerosis JO - Mult Scler VL - 23 UR - https://doi.org/10.1177/1352458517690821 DO - 10.1177/1352458517690821 ID - Benedict2017 ER - TY - JOUR AU - Reilly, M. C. AU - Zbrozek, A. S. AU - Dukes, E. M. PY - 1993 DA - 1993// TI - The validity and reproducibility of a work productivity and activity impairment instrument JO - PharmacoEconomics VL - 4 UR - https://doi.org/10.2165/00019053-199304050-00006 DO - 10.2165/00019053-199304050-00006 ID - Reilly1993 ER - TY - STD TI - Tjalf Ziemssen, Jan Hillert, Helmut Butzkueven. The importance of collecting structured clinical information on multiple sclerosis. BMC Med. 2016;14(1). ID - ref25 ER - TY - STD TI - Ziemssen T, Berthold H, Dirks P, Evershed J, Gunzenhauser K, Leemhuis J, et al. Integration of ocrelizumab safety data from the German study CONFIDENCE into the global post-marketing safety studies MANUSCRIPT and VERISMO. ECTRIMS Online Library 2018, 229464. https://onlinelibrary.ectrims-congress.eu/ectrims/2018/ectrims-2018/229464/tjalf.ziemssen.integration.of.ocrelizumab.safety.data.from.the.german.study.html. Accessed 15 Apr 2019. UR - https://onlinelibrary.ectrims-congress.eu/ectrims/2018/ectrims-2018/229464/tjalf.ziemssen.integration.of.ocrelizumab.safety.data.from.the.german.study.html ID - ref26 ER -